Osmind

We are excited to announce a landmark collaboration with the American Psychiatric Association (APA) to advance quality psychiatric care and accelerate research. "At Osmind, we emphasize the importance of clinicians participating in evidence-generating medicine to help shape the future of mental health care, especially as the psychiatric field begins to embrace new treatments and precision psychiatry,” says Carlene MacMillan, MD, Chief Medical Officer of Osmind. “Clinicians in private practice juggle many competing demands so it is crucial we make participation both easy and worthwhile to them." To make participation in evidence-generating medicine easier for busy private practitioners, we’re integrating APA's diagnostic and outcomes measures directly into the Osmind EHR. We're starting with the DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure, which joins our library of 40+ measures, enabling clinicians to contribute to research at the point of care. We’ll also explore an integration between the Osmind EHR and PsychPRO so that clinicians using the Osmind EHR can participate effortlessly in the PsychPRO registry. "PsychPRO is the tool healthcare organizations need to guide their efforts to deliver quality mental health care and improve patient outcomes," says Nitin Gogtay, M.D., APA Chief of Research and Deputy Medical Director. "Our collaboration with Osmind will allow us to strengthen PsychPRO today, and long-term offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.” We are delighted to work with the APA, and proud to enable independent practices to contribute to the evolution of the field and elevate their own evidence-based practices. https://lnkd.in/g4RU7Ftt

Forward-Thinking Mental Health Clinicians: Running a solo private practice doesn't mean you have to go it alone. The right psychiatry EHR can make all the difference. Here's what your colleagues are saying: "It can be very intimidating to start a solo private practice, but becoming a part of this supportive community and using an intuitive EMR has made the process much smoother." -Maegen Vincent, MD, Adolescent, Young Adult, and Reproductive Psychiatrist "Osmind is really paying for itself. My patients love having the app. It's truly a game changer." -Bergina Isbell, MD, Psychiatrist Why are forward-thinking mental health clinicians choosing Osmind? 1️⃣ Community Support: Join a network of like-minded professionals, attend live events, and contribute to transforming mental health care. 2️⃣ Streamlined Operations: Simplify scheduling and billing, making your front and back-office tasks a breeze. 3️⃣ Efficient Charting: Save time with customizable templates and automated progress monitoring. 4️⃣ Enhanced Patient Experience: Offer a user-friendly patient app for easy scheduling, secure messaging, and engagement. 5️⃣ Reduced Burnout: As Dr. Appasani put it, "It just makes it less burdensome and it takes away that level of burnout." Ready to elevate your practice and join the community of forward-thinking psychiatrists? Learn how the right EHR can transform your practice.

🧠 What if treating depression and anxiety became as precise as treating cancer? "We're about halfway up the mountain," says Osmind CEO, Lucia Huang. Like oncology decades ago, psychiatry is evolving from subjective assessments toward more precise, objective measurements of mental health. 💡 The landscape is shifting in remarkable ways. Lucia sat down with Zachary Haigney on The Trip Report by Beckley Waves and discuss: -"Interventional psychiatry" will simply become "psychiatry" as traditional boundaries dissolve and treatments ranging from TMS to psychedelic-assisted therapies and metabolic approaches will all become tools in the psychiatry toolbelt. -Real-world data shows psychiatrists spend an extra 3 hours daily on admin - underscoring the need for better systems. Clinician-entrepreneurs are leading a movement toward practice autonomy and innovative care/ -New infrastructure (like Osmind’s Learning Health System) is emerging to support treatment innovation—much like charging networks enabled EV adoption -The promise and challenges of incorporating biomarkers and real-world evidence into psychiatric care -This convergence of fresh philosophies, emerging technologies, and breakthrough treatments points to a future where mental healthcare becomes more precise, accessible, and effective. Osmind's Learning Health System lets clinicians track patient outcomes systematically as they adopt innovative treatments like TMS, SPRAVATO®, and ketamine. 🎧 Listen to the full episode on your favorite podcast platform or here: https://lnkd.in/dyRHEg9V

Congrats to Osmind's Chief Medical Officer, Carlene MacMillan, MD, FCTMSS,DFAACAP for being named a Distinguished Fellow at the American Academy of Child and Adolescent Psychiatry (AACAP). Dr. MacMillan's journey with AACAP began as a medical student through their mentorship program, and she has since become a driving force in the organization. She currently serves as: -Co-Chair of the Public Resources Committee -Member of the AI Resource Group -Featured speaker, delivering 5 presentations at this year's conference Congrats on this well-deserved recognition, Dr. MacMillan—excited to see what you do next! 🎉

Exciting news! 🎉 Osmind is partnering with UBC to create a first-of-its-kind EHR integration for REMS in mental health care. REMS (Risk Evaluation and Mitigation Strategies) are FDA-required programs to ensure that the benefits of certain medications outweigh their risks. They're crucial for patient safety, but can be complex to implement and add friction to care workflows. Our partnership advances: -Better patient care: Prescribers stay in their workflow for REMS documentation -Reduced operational overhead: Eliminates manual processing and faxes -Improved data quality: Direct EHR-to-REMS integration with streamlined data validation -Enhanced REMS efficiency: Faster safety notifications and simplified monitoring -Increased REMS compliance: For prescribers, administrators, and sponsors -Improved treatment efficiency: Increase clinic efficiency and capacity to help more patients "This is an important initial step for standards adoption and for actualizing the promise of reduced burden, improved REMS compliance, and superior data quality," says Nathan Thompson, CIO at UBC. "Innovation in mental health care is advancing rapidly, but a significant gap remains between research and real-world patient care," adds Jimmy Qian, Co-founder and President at Osmind. By combining Osmind's psychiatric platform with UBC's REMS expertise, we're bridging the gap between cutting-edge research and real-world implementation. Discover how this partnership is advancing mental health treatment and research: https://lnkd.in/dZM2-Eb7

Five years ago, SPRAVATO® (esketamine) gained FDA approval, marking psychiatry's first novel antidepressant mechanism in six decades. But how did we get here? In our latest Psychiatry Tomorrow episode, Osmind Strategic Advisor and pioneer, Husseini Manji, M.D., F.R.C.P.C., and Osmind's VP of Scientific Affairs, L. Alison McInnes MD, MS, share the untold story of bringing this groundbreaking treatment from lab to clinic. From treating patients who had failed six different medications to developing an entirely new drug delivery system, the journey offers crucial lessons for the future of psychedelic medicine development. What you'll discover: -The science behind rapid-acting antidepressants and neuroplasticity -How the team engineered a practical solution for ketamine delivery -Inside the rigorous 26-study FDA approval process -The fight for mental health parity in insurance coverage -A potential roadmap for future psychedelic medicine approval Whether you're a clinician considering offering SPRAVATO®, a researcher developing novel psychiatric medications, or simply curious about the future of depression treatment, this episode provides insights from the pioneer who made it happen. Read the full story or listen to the episode below 👇 https://lnkd.in/dKG_WTJp Or search "Psychiatry Tomorrow" on your favorite podcast player.

Who's attending? Our Chief Medical Officer and FACTMS Board member, Carlene MacMillan, MD, FCTMSS,DFAACAP, will be there!

Today is #WorldMentalHealthDay, a day to unite and support those facing mental health challenges worldwide. The numbers are staggering: -264 million people worldwide suffer from depression -Over 70 million live with PTSD -Mental health disorders are projected to cost the global economy $6 trillion by 2030 Yet, for many, effective treatment remains out of reach. After the 2nd anti-depressant, a patient’s likelihood of remission is only 10-20%. At Osmind, we're working to change this. We're empowering clinicians with tools to: -Streamline care -Collect real-world evidence and implement measurement-informed care -Accelerate research on breakthrough treatments Our goal? A world where effective mental health care is accessible to all who need it. Thank you to everyone reading this who is committed to transforming mental healthcare. Together, we can bring hope to millions.

Exciting: The first novel schizophrenia treatment in 70 years has arrived! 🧠💊 Cobenfy™ (KarXT) just received FDA approval, and it's drawing significant attention in the psychiatric community. Here's why it's promising: -Innovative mechanism: Targets muscarinic receptors, not dopamine -Encouraging efficacy: Reduces both positive and negative symptoms -Noteworthy safety profile: No black box warning or movement disorders What does this mean for clinicians and patients? Our latest deep dive unpacks: ✅ The science behind Cobenfy™ ✅ Clinical evidence from EMERGENT trials ✅ Practical considerations for prescribing ✅ Future implications for schizophrenia treatment Whether you're a psychiatrist, researcher, or simply curious about mental health innovations, this guide offers valuable insights. Ready to explore the future of schizophrenia care? Check out our comprehensive guide: https://lnkd.in/gzZkishN

As a mental health clinician, you’ve probably heard countless myths about Measurement-Based Care (MBC). Let’s look at the facts: 🧠📊 Myth: MBC makes therapy impersonal. Fact: It strengthens the therapeutic relationship and improves communication. Myth: MBC wastes precious session time. Fact: It streamlines therapy and can nearly double therapeutic effect size. Myth: Clinical judgment is all you need. Fact: MBC enhances your expertise, helping catch 80% more cases of clinical deterioration. Myth: It oversimplifies complex mental health issues. Fact: MBC offers a nuanced, comprehensive view of patient progress, and lends deeper insights into your patients' experiences. Myth: Implementing MBC is a headache. Fact: Modern tech like Osmind makes it easy. Read on for a concise resource dispelling myths about MBC: https://bit.ly/3XNpNOQ